Lazard Asset Management
BPMC

Lazard Asset Management’s Blueprint Medicines BPMC Stock Holding History

Lazard Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,348
Closed -$172K – 1874
2025
Q2 		$172K Sell
1,348
-15,864
-92% -$1.65M ﹤0.01% 1737
2025
Q1 		$1.52M Buy
17,212
+15,834
+1,149% +$1.54M ﹤0.01% 1057
2024
Q4 		$118K Sell
1,378
-8,772
-86% -$803K ﹤0.01% 1751
2024
Q3 		$937K Buy
10,150
+4,485
+79% +$446K ﹤0.01% 1104
2024
Q2 		$610K Buy
5,665
+3,007
+113% +$301K ﹤0.01% 1126
2024
Q1 		$251K Buy
+2,658
New +$228K ﹤0.01% 1232
2023
Q3 		– Sell
-1,103
Closed -$69K – 2272
2023
Q2 		$69K Buy
+1,103
New +$60K ﹤0.01% 1720
2023
Q1 		– Sell
-1,312
Closed -$57K – 2307
2022
Q4 		$57K Buy
+1,312
New +$62.9K ﹤0.01% 1737
2021
Q4 		– Sell
-11,277
Closed -$1.16M – 2299
2021
Q3 		$1.16M Buy
+11,277
New +$1.05M ﹤0.01% 1041
2021
Q1 		– Sell
-824
Closed -$92K – 1863
2020
Q4 		$92K Buy
+824
New +$86.8K ﹤0.01% 1204

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Lazard Asset Management's BPMC Position: Q3 2025 in Review

Lazard Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,348 shares — an estimated $172K sold.

Lazard Asset Management first reported a position in BPMC in Q4 2020 and held it in 10 quarters. The position peaked at $1.52M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Lazard Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 1,348 Blueprint Medicines shares in Q3 2025, an estimated $172K.
  • Lazard Asset Management first reported a position in Blueprint Medicines in Q4 2020 and held it in 10 quarters.
  • Lazard Asset Management's Blueprint Medicines position peaked at $1.52M in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.